We founded Cue Health, executing from an idea to category-creating technology for molecular diagnostics at home that received full FDA De Novo authorization. We authored 100+ granted patents, built ISO 13485-compliant manufacturing lines producing tens of millions of units, scaled bioproduction of enzymes and antibodies, took the company public, and generated $1.3 billion in revenue.
Cancer has an adaptive intelligence that has outmaneuvered medicine’s best efforts.
We are developing a new way in, a platform for biological control, to overcome the deadliest cancers.